ReviewJournal of hematology2022
Treatment of Light Chain Deposition Disease: A Systematic Review.
Review in Journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- IgG-type lymphoplasmacytic lymphoma with light chain deposition disease.CEN case reports · 2026Article
- Pulmonary light chain deposition disease secondary to Sjögren disease: a case report.Frontiers in immunology · 2026Article
- Myopathies Associated With Monoclonal Gammopathies of Clinical Significance: A Narrative Review.Cureus · 2025Review
- Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies.Annals of hematology · 2025Review
- Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature.Frontiers in oncology · 2025Article
- Markedly T2-Hypointense Clival Plasmacytoma With Light Chain Deposition Disease: A Case Report.Cureus · 2024Article
- Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review.Experimental and therapeutic medicine · 2024Article
- Successful Treatment with Daratumumab of a Patient with Monoclonal Lambda Light Chain Disease Presenting as Nephrotic Syndrome and Crescentic Glomerulonephritis.Acta haematologica · 2024Article
- Treatment and Outcome of Light Chain Deposition Disease in the Era of Novel Agents and Transplant.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.Indian journal of nephrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Light chain deposition disease (LCDD) is a rare hematologic disorder that can affect any organ but predominantly involves the kidneys. Existing literature is limited to case reports and small single-center retrospective series, explaining the lack of any treatment algorithms and management guidelines for patients with this disorder. In this systematic review of literature, we explored the role of standard and high-dose chemotherapy-autologous stem cell transplant for LCDD. A total of 11 studies were identified to evaluate the hematologic and renal responses to various treatment regimens. Autologous stem cell transplant and bortezomib-based regimens appear to have reasonable safety and efficacy for this rare hematologic disorder, albeit some statistical and analytical limitations. Large multicenter retrospective and prospective studies are needed to better elucidate the role of various chemotherapy regimens as well as autologous stem cell transplant for patients with LCDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.